Ongentys

Generic name: opicapone

Drug class: Dopaminergic antiparkinsonism agents

Dosage form: Capsules

Root of administration: Oral

Dose: 50 mg orally once a day at bedtime

Mechanism of action: Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), an enzyme that metabolizes levodopa. By inhibiting COMT, opicapone increases the availability of levodopa to the brain, thereby reducing “off” episodes in patients with Parkinson’s disease.

Drug usage cases:

• Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes

Drug contraindications:

• Concomitant use of non-selective monoamine oxidase (MAO) inhibitors
• Pheochromocytoma
• Paraganglioma

Side effects:

• Dyskinesia
• Dizziness
• Constipation
• Dry mouth
• Hallucinations
• Impulse control disorders (e.g., gambling, binge eating, compulsive shopping)
• Orthostatic hypotension
• Weight loss

Warnings:

• May cause sudden sleep episodes during daily activities
• Monitor blood pressure regularly
• Use caution when driving or operating machinery until effects are known
• Discontinue if neuroleptic malignant syndrome or rhabdomyolysis occurs
• Monitor for signs of impulse control disorders

Use during pregnancy or breastfeeding: Safety and efficacy during pregnancy and breastfeeding have not been established. Use only if the potential benefit justifies the potential risk to the fetus or nursing infant. Consult a healthcare provider before use.